[先进治疗药品]。

Q4 Medicine

Ugeskrift for laeger Pub Date : 2026-08-24 DOI:10.61409/V12251027

Rasmus Roost Aabling, Anne Louise Schacht Revenfeld, Maria Rusan

{"title":"[先进治疗药品]。","authors":"Rasmus Roost Aabling, Anne Louise Schacht Revenfeld, Maria Rusan","doi":"10.61409/V12251027","DOIUrl":null,"url":null,"abstract":"Advanced therapy medicinal products are a rapidly expanding drug class based on genes, cells, and tissues, transforming the treatment of diseases, including haematologic cancers and genetic disorders, such as sickle cell disease and haemophilia. This review highlights that successful clinical implementation requires coordinated national strategies, regulatory support, sustainable funding, robust clinical and production infrastructure, and trained specialised personnel to ensure timely, safe, and equitable patient access.","PeriodicalId":23428,"journal":{"name":"Ugeskrift for laeger","volume":"188 35","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Advanced therapy medicinal products].\",\"authors\":\"Rasmus Roost Aabling, Anne Louise Schacht Revenfeld, Maria Rusan\",\"doi\":\"10.61409/V12251027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advanced therapy medicinal products are a rapidly expanding drug class based on genes, cells, and tissues, transforming the treatment of diseases, including haematologic cancers and genetic disorders, such as sickle cell disease and haemophilia. This review highlights that successful clinical implementation requires coordinated national strategies, regulatory support, sustainable funding, robust clinical and production infrastructure, and trained specialised personnel to ensure timely, safe, and equitable patient access.\",\"PeriodicalId\":23428,\"journal\":{\"name\":\"Ugeskrift for laeger\",\"volume\":\"188 35\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2026-08-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ugeskrift for laeger\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.61409/V12251027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ugeskrift for laeger","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61409/V12251027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

先进治疗药物是基于基因、细胞和组织的快速扩大的药物类别，改变了疾病的治疗，包括血液病癌症和遗传疾病，如镰状细胞病和血友病。该综述强调，成功的临床实施需要协调一致的国家战略、监管支持、可持续的资金、健全的临床和生产基础设施以及训练有素的专业人员，以确保及时、安全和公平地获得患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Advanced therapy medicinal products].

Advanced therapy medicinal products are a rapidly expanding drug class based on genes, cells, and tissues, transforming the treatment of diseases, including haematologic cancers and genetic disorders, such as sickle cell disease and haemophilia. This review highlights that successful clinical implementation requires coordinated national strategies, regulatory support, sustainable funding, robust clinical and production infrastructure, and trained specialised personnel to ensure timely, safe, and equitable patient access.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ugeskrift for laeger Medicine-Medicine (all)

CiteScore

0.20

自引率

0.00%

发文量

345

期刊介绍： The Ulster Medical Journal is an international general medical journal with contributions on all areas of medical and surgical specialties relevant to a general medical readership. It retains a focus on material relevant to the health of the Northern Ireland population. The Honorary Editor would welcome offers of papers for publication. Prospective authors are invited to read the notice to contributors.